Novavax, Inc. announced that it will present strategic and business updates at the 2024 Jefferies London Healthcare Conference on November 20, 2024. The update, referred to as the Investor Presentation, will be made available on the company's website and is attached as Exhibit 99.1 to the current report on Form 8-K. The presentation will cover various aspects of the company's operations, including corporate strategy, operating plans, partnerships, and financial guidance for the full year 2024. It will also address the development and potential market demand for Novavax's COVID-19 vaccine and other product candidates. The company highlighted forward-looking statements in the report, cautioning that they involve risks and uncertainties that could cause actual results to differ materially from those projected. These statements include expectations regarding manufacturing capacity, regulatory filings, market sizes, and financial performance, among others. Novavax also mentioned potential risks such as manufacturing and distribution challenges, regulatory hurdles, and market acceptance of their products.

Novavax, Inc. announced that it will present strategic and business updates at the 2024 Jefferies London Healthcare Conference on November 20, 2024. The update, referred to as the Investor Presentation, will be made available on the company's website and is attached as Exhibit 99.1 to the current report on Form 8-K. The presentation will cover various aspects of the company's operations, including corporate strategy, operating plans, partnerships, and financial guidance for the full year 2024. It will also address the development and potential market demand for Novavax's COVID-19 vaccine and other product candidates. The company highlighted forward-looking statements in the report, cautioning that they involve risks and uncertainties that could cause actual results to differ materially from those projected. These statements include expectations regarding manufacturing capacity, regulatory filings, market sizes, and financial performance, among others. Novavax also mentioned potential risks such as manufacturing and distribution challenges, regulatory hurdles, and market acceptance of their products.